# Celcuity Inc. (CELC) — capital_raise/public_offering [announced]
Source: sec.gov · situation sit_032ff7fec14fcd0a1bca · public 4365475181490926478 · retrieved 2026-08-19T11:30:42.826Z

## Overview
Celcuity Inc. is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications; its lead product REVTORPYK (gedatolisib) was FDA-approved in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer.

Celcuity Inc. completed a public offering of 0.250% convertible senior notes due 2032 in June 2026. The gross offering size was $575.0 million, with net proceeds of $557.2 million after deducting underwriting discounts, commissions, and estimated offering expenses. The company used $137.0 million of the net proceeds to prepay existing term loan debt.

## Terms
- Deal value: $575.0M · Consideration: cash

## Key dates
- Announced 2026-08-13 · Expiry 2032-06-30

## Timeline
- 2026-08-13 · 8-K (0001193125-26-349227): 8-K - Celcuity Inc. — *Celcuity Inc. is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications; its lead product REVTORPYK (gedatolisib) was FDA-approved in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer.* Celcuity Inc. completed a public offering of 0.250% convertible senior notes due 2032 in June 2026. The gross offering size was $575.0 million, with net proceeds of $557.2 million after deducting underwriting discounts, commissions, and estimated offering expenses. The company used $137.0 million of the net proceeds to prepay existing term loan debt.
  https://www.sec.gov/Archives/edgar/data/1603454/0001193125-26-349227.txt

## Citations
- 0001193125-26-349227 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526349227